Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 vs Docetaxel in KRAS G12D-mutant NSCLC
NCT07668752Phase 3Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Jul 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 3 trial of GFH375 in non-small cell lung cancer (NSCLC), sponsored by GenFleet Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
GFH375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07668752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668752.